Document:

Consulting Agreement

 EXHIBIT 10.112 
  
 AEOLUS PHARMACEUTICALS, INC. 
  

December 14, 2004 
  
 Dr. Shayne C. Gad 
 Aeolus Pharmaceuticals, Inc. 
 P.O. Box 14287 
 79 T.W. Alexander Drive 
 4401 Research Commons, Suite 200 
 Research Triangle Park, NC 27709 
  
 Dear Shayne: 
  
 This letter confirms our conversations regarding extending your consulting period with Aeolus Pharmaceuticals, Inc. (“Aeolus” or the
“Company”) and sets forth the terms and conditions of that consulting. 
  
 The Company hereby offers to extend the term of your consulting agreement. During the period of your consulting, you shall devote yourself for two business days each week to work for or at the direction of the
Company’s Chief Executive Officer, use your best efforts to complete all assignments, and adhere to the Company’s procedures and policies in place from time-to-time. 
  
 You will receive a monthly consulting fee of $19,500 for each full month of consulting. In addition, for each full month of
consulting, the Company will grant you an option to purchase 2,500 shares of the Company’s stock at fair market value pursuant to the terms of the Company’s 2004 Stock Option Plan. The options will be fully vested upon grant. 

 
 Currently, we anticipate that you will continue as a consultant for an
additional term of twelve months from January 1, 2005. However, the Company may terminate your consulting earlier for any reason at its sole discretion. In the event that the Company elects to terminate your consulting prior to the full term of this
agreement, you will be given two (2) months notice before termination. 
  
 By executing this letter below, you agree that during the course of your consulting and thereafter that you shall not use or disclose, in whole or in part, any of the Company’s trade secrets, confidential and proprietary information,
including customer lists and information, to any person, firm, corporation, or other entity for any reason or purpose whatsoever other than in the course of your employment with the Company or with the prior written permission of the Company. By
signing this letter below, you further acknowledge that you have no claims against the Company up to the date of your signature and delivery of this letter. 

 All findings, conclusions and date and all methods, inventions, discoveries, trade secrets, techniques,
processes and know-how, whether or not patentable, that are made by you, either alone or with others, in the performance of your services or which result, to any extent, from use of Aeolus’ materials, premises or other property (collectively,
“Inventions”) shall become the exclusive property of Aeolus. You hereby assign, transfer and convey all of your rights, title and interest in and to any and all Inventions. Upon the request and at the expense of Aeolus, you will execute
and deliver any and all instruments and documents and take such other acts as may be necessary or desirable to document Aeolus’ rights or to enable Aeolus to apply for, prosecute and enforce patents, trademark registrations or copyrights in any
jurisdiction with respect to any Inventions or to obtain any extension, validation, re-issue, continuance or renewal of any such intellectual property right. 
  
 You are an independent contractor under this agreement and shall not be deemed an employee of Aeolus. You will not be entitled to participate in any
benefit plan of an Aeolus employee. 
  
 Kindly sign your name at
the end of this letter to signify your understanding and acceptance of these terms and that no one at the Company has made any other representation to you. We look forward to continuing our relationship with you. 
  

	
	 Sincerely,

	
	 /s/ James D. Crapo

	 James D. Crapo, M.D.

	 Chief Executive Officer

  

	
	 Agreed to and

	 Accepted by:

	
	 /s/ Shayne C. Gad

	 Shayne C. Gad

	
	 December 14, 2004

	 Date

  

 2Code of Ethics for Chief Executive Officer and Senior Financial Officers

 EXHIBIT 10.113 
  
 AEOLUS PHARMACEUTICALS, INC. 
  

Code of Ethics for Chief Executive Officer and Senior Financial Officers 
  
 The Company’s Chief Executive Officer and its senior financial officers, including the Chief Financial Officer,
Controller and other similar employees, due to their important and elevated role in the Company’s corporate governance, must comply with the following standards of conduct: 
  

	•	Act with honesty and integrity, avoiding actual or apparent conflicts of interest in personal and professional relationships. 

  

	•	Act in good faith, responsibly, with due care, competence and diligence, without misrepresenting material facts or allowing their independent judgment to be subordinated.

  

	•	Create and provide information to the SEC and the public that is full, fair, accurate, timely and understandable. 

  

	•	Comply with applicable laws, rules and regulations of federal, state and local governments, and applicable private and public regulatory agencies. 

  

	•	Comply with applicable accounting rules and pronouncements. 

  

	•	Respect the confidentiality of information acquired in the course of their work except when authorized or otherwise legally obligated to disclose such information. Confidential
information acquired in the course of their work may not used for personal advantage.  

  

	•	Use responsibly and as authorized all assets and resources employed or entrusted to them. 

  
 It is the responsibility of the CEO and each senior financial officer promptly to bring to the attention of the Audit Committee: 

 

	•	any material information of which he or she may become aware that affects the disclosures made by the Company in its public filings; 

  

	•	any information he or she may have concerning (a) significant deficiencies in the design or operation of internal controls which could adversely affect the Company’s ability to
record, process, summarize and report financial data or (b) any fraud, whether or not material, that involves any director, officer or other employee who has a significant role in the Company’s financial reporting, disclosure or internal
controls for disclosure and financial reporting; 

  

	•	any information he or she may have concerning any violation of this Code of Ethics or the Company’s Code of Business Conduct, including any actual or apparent conflicts of
interest 

 between personal and professional relationships, involving any director, officer or other employee who
has a significant role in the Company’s financial reporting, disclosure or internal controls for disclosure and financial reporting; and 
  

	•	any information he or she may have concerning evidence of any violation of the securities or other laws, rules or regulations applicable to the Company and the operation of its
business, by the Company or any agent thereof, or of violation of this Code of Ethics or the Code of Business Conduct. 

  
 The Board of Directors shall determine, or designate appropriate persons to determine, appropriate actions to be taken in the event of violations of this Code of Ethics.
Such actions shall be reasonably designed to deter wrongdoing and to promote accountability for adherence to this Code of Ethics, and may include written notices to the individual involved that the Board has determined that there has been a
violation, censure by the Board, demotion or re-assignment of the individual involved, suspension with or without pay or benefits (as determined by the Board) and termination of the individual’s employment. In determining what action is
appropriate in a particular case, the Board of Directors or such designee shall take into account all relevant information, including the nature and severity of the violation, whether the violation was a single occurrence or repeated occurrences,
whether the violation appears to have been intentional or inadvertent, whether the individual in question had been advised prior to the violation as to the proper course of action and whether or not the individual in question had committed other
violations in the past. 
  

 2EXHIBIT 4.1

 Exhibit 4.1 

  

			
	No.     	 	                     Shares

  
 NEW ROME BANCORP,
INC. 
 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE 
  
 This Certifies that
                                       
                                        
                  is the owner of 
  
 _________________________________________________________ 
 fully paid and non-assessable shares of common stock $.01 par value per share, of 
  
 New Rome Bancorp, Inc. 
  
 (“the Corporation”), a corporation formed under the laws of the State of Delaware. The shares represented by this Certificate are transferable only on the
stock transfer books of the Corporation by the holder of record hereof, or by his or her duly authorized attorney or legal representative, upon the surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned
and registered by the Corporation’s transfer agent and registrar. The shares represented by this Certificate are not insured by the Federal Deposit Insurance Corporation or by any other Government agency. 
  
 In Witness Whereof, the Corporation has caused this Certificate to be
executed by the facsimile signature of its duly authorized officers and has caused a facsimile of its corporate seal to be hereunto affixed. 
  

					
	 Dated:                     ,
20    
	 	 	 	 
			
	  	 	 	 	  
	 Marion C. Scoville
 Secretary
	 	 	 	 Charles M. Sprock
 President and Chief Executive Officer

  

  

  
 NEW
ROME BANCORP, INC. 
  
 The shares represented by this Certificate are issued subject to all the provisions of the Certificate of Incorporation and By-laws of NEW ROME BANCORP, INC. (the “Corporation”) as from time to time amended (copies of which are on
file at the principal office of the Corporation), to all of which the holder by acceptance hereof assents. The following description constitutes as summary of certain provisions of and is qualified in its entity by reference to, the Certificate of
Incorporation. 
  
 The Certificate of Incorporation of the
Corporation contains certain provisions, applicable upon the effective date of the consummation of the reorganization of The Rome Savings Bank (the “Bank”) from a mutual holding company structure to a savings and loan holding company
structure and the concurrent acquisition by the Corporation of all the outstanding capital stock of the Bank. The Certificate of Incorporation provides that no person (other than the Corporation), any subsidiary or any pension, profit-sharing, stock
bonus or other compensation plan maintained by the Corporation, or by a member of a controlled group of corporations or trades or business of which the Corporation is a member for the benefit of the employees of the Corporation or any subsidiary, or
any trust or custodial arrangement established in connection with any such plan) shall directly or indirectly acquire or hold the beneficial ownership of more than then percent (10%) of the issued and outstanding shares of the Voting Stock of the
Corporation. The Certificate of Incorporation contains an provision pursuant to which the holders of shares in excess of 10% of the Voting Stock of the Corporation are limited to (1/100) of a vote per share with respect to such shares in excess of
the 10% limitation. In addition, the Corporation is authorized to refuse to recognize and transfer or attempted transfer of any shares of Voting Stock to any person who beneficially owns, or who the Corporation believes would become by virtue of
such transfer the beneficial owner of more than ten percent (10%) of shares. 
  
 The Certificate of Incorporation of the Corporation contains provisions providing that the affirmative vote of the holders of at least 10% of the Voting Stock of the Corporation may be required to approve certain
business combinations and other transactions with persons who directly or indirectly acquire or hold the beneficial ownership of in excess of 10% of the Voting Stock of the Corporation. 
  
 The Corporation will furnish to any stockholder upon written request and without charge, a statement of the powers,
designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations, or restrictions of such preferences and/or rights. Such request may be made to the
Corporation of to its transfer agent and registrar. 
  
 The
following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable law or regulations. 
  

													
	 TEN COM
	  	–	  	as tenants in common	  	UNIF Transfers TO MIN ACT	 	 	  	 
	 TEN ENT
	  	–	  	as tenants by the entireties	  	Custodian	  	 
	 JT TEN
	  	–	  	as joint tenants and not as tenants in common	  	 
	 	  	 	  	  	(Cust)	  	 	 	 	  	(Minor)
	 	  	 	  	 	  	 
	 	  	 	  	 	  	(State)	  	 	 	 	  	 

  
 Additional
Abbreviations may also be used through not in the list above 
  
 For value
received,
                                        
                                        
                             herby sell(s), assign(s) and transfer(s) unto    
                                           
                                                 
                                                 
                                                 
                                             shares of Common
Stock evidenced by this Certificate, and do(es) hereby irrevocably constitute(s) and appoint(s)
                                        
                             as Attorney, to transfer the said shares on the books of the herein named
Corporation, with full power of substitution. 
  

									
	 Date:
                            
	 	 	 	 Signature:
	 	 _____________________________________

	 	 	 	 	 Signature:
	 	 _____________________________________

					
	 	 	 	 	 	 	 NOTICE:
	 	The signature to this assignment must correspond with the name as written upon the face of this Certificate, in every particular, without alteration or enlargement, or any change
whatsoever.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]